Innoviva, Inc.

What they do

Innoviva earns royalties from GSK on sales of RELVAR/BREO ELLIPTA and ANORO ELLIPTA, and sells critical care and infectious disease products through its IST subsidiary, including GIAPREZA, XACDURO, XERAVA, and ZEVTERA. It also holds strategic investments in healthcare assets, including Armata Pharmaceuticals, and launched Nortiva Bio for long-acting oral drug delivery.

Revenue drivers

• GSK royalty portfolio — Gross royalty revenue from GSK was $59.8M in Q2 2026, roughly 50% of total revenue, with stable quarter-over-quarter performance.
• IST net product sales — Net product sales were $51.8M in Q2 2026, up 46% YoY, with U.S. sales of $36.6M (26% YoY growth) and ex-U.S. sales of $15.2M.
• GIAPREZA (IST product) — U.S. net product sales of $21.0M in Q2 2026, the largest IST product contributor.
• XACDURO (IST product) — U.S. net product sales of $12.0M in Q2 2026; an exclusive distribution and licensing agreement with Dr. Reddy's Laboratories was signed to expand access in emerging markets.

Recent performance

Q2 2026 total revenue was $119.6M, up 19% YoY from $100.3M. Royalty revenue was $59.8M, up 2% from Q1 2026. Net product sales grew 46% YoY to $51.8M. However, net loss was $83.4M, or $1.14 basic loss per share, due to a $161.0M unfavorable fair value change on equity and long-term investments, primarily from Armata's lower share price. Cash and equivalents were $570.4M as of June 30, 2026.

Strategy

Management emphasizes durable cash generation from royalties and operating revenue growth at IST, targeting at least $150M in IST U.S. net product sales in 2026. They are expanding XACDURO's geographic reach via the Dr. Reddy's licensing deal and launched Nortiva Bio to develop its LYNX long-acting oral drug delivery platform. The company continues to execute share repurchases and is managing strategic investments in healthcare assets.

Risks

• Royalty concentration — A significant portion of revenue depends on GSK sales of respiratory products, and lower-than-expected future royalty revenue could materially affect results.
• Investment fair value volatility — Net income is highly sensitive to fair value changes in equity and long-term investments, as evidenced by a $161.0M unfavorable adjustment in Q2 2026.
• Product commercialization risk — IST products face commercial adoption risks in the U.S. and ex-U.S. markets, and slower-than-expected commercial uptake could hurt growth.
• Clinical and regulatory delays — Product candidates may face delays or failures in clinical studies and regulatory approvals, impacting future revenue potential.

Outlook

Management expects continued growth in IST net product sales with guidance of at least $150M in U.S. sales for 2026. The royalty portfolio is expected to remain stable, and the company will continue to invest in strategic growth opportunities, including Nortiva Bio, while actively repurchasing shares. No specific forward revenue guidance was provided beyond these targets.